Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 EUR | -1.86% | -9.64% | -19.47% |
Apr. 15 | Sanofi: progress in hematology trial | CF |
Apr. 15 | Innate Pharma: progress in hematology trial | CF |
Sales 2024 * | 46.78M 49.84M | Sales 2025 * | 74.41M 79.27M | Capitalization | 171M 182M |
---|---|---|---|---|---|
Net income 2024 * | -25M -26.63M | Net income 2025 * | -21M -22.37M | EV / Sales 2024 * | 2.24 x |
Net cash position 2024 * | 65.68M 69.97M | Net cash position 2025 * | 122M 130M | EV / Sales 2025 * | 0.66 x |
P/E ratio 2024 * |
-14.6
x | P/E ratio 2025 * |
3.49
x | Employees | 179 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.3% |
Latest transcript on Innate Pharma
1 day | -1.86% | ||
1 week | -9.64% | ||
Current month | -3.43% | ||
1 month | -4.74% | ||
3 months | -13.88% | ||
6 months | -7.86% | ||
Current year | -19.47% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Vivier
FOU | Founder | 60 | 99-09-22 |
Chief Executive Officer | 62 | 99-09-22 | |
Frederic Lombard
DFI | Director of Finance/CFO | 49 | 21-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 99-09-22 | |
Gilles Brisson
BRD | Director/Board Member | 72 | 07-06-25 |
Olivier Martinez
BRD | Director/Board Member | 54 | 10-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 2.11 | -1.86% | 61,255 |
24-04-18 | 2.15 | -0.46% | 72,009 |
24-04-17 | 2.16 | -1.82% | 126,844 |
24-04-16 | 2.2 | -2.65% | 88,136 |
24-04-15 | 2.26 | -3.21% | 89,612 |
Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.47% | 185M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- IPH Stock